Regulatory decisions affecting biopharma products in development, including approvals, recommendations, rejections and the granting of regulatory pathways in December 2019.
Whether the dealmaking momentum of 2019 will continue into 2020 is at the mercy of several uncertainties, not the least of which is the outcome of a U.S. presidential election and continued debates over drug pricing and other legislative issues affecting the industry.
RSS
